Reuters logo
BRIEF-Contravir's CRV431 potently inhibits essential pathway in hepatitis B
December 8, 2016 / 11:53 AM / a year ago

BRIEF-Contravir's CRV431 potently inhibits essential pathway in hepatitis B

Dec 8 (Reuters) - Contravir Pharmaceuticals Inc -

* Contravir’s cyclophilin inhibitor CRV431 potently inhibits essential pathway in hepatitis B

* Inhibitor CRV431, shows it effectively blocks a critical interaction between HBV X protein, host Cyclophilin A, with nanomolar potency Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below